Drug Trial Radar · NCT07773129
A Study to Learn How ASP3082 is Processed in Healthy Men
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Aug 28, 2026
Primary completion
Oct 20, 2026
Study completion Oct 20, 2026
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Aug 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Setidegrasib (ASP3082) is being developed for certain cancers. In this study, the researchers want to understand how it is processed by the body in healthy male volunteers. To do this, \[14C\] which is a certain chemical (called a tracer, or radionuclide) has been added to setidegrasib. \[14C\] gives off radiation, but the dose is very low (about the same as the dose from an x-ray) and will leave the body within a few days. \[14C\] will be picked up by a scanner and will be used to follow setidegrasib through the body. \[14C\]setidegrasib will be given as 1 single injection slowly through a vein (infusion). The men will stay overnight in the clinic for at least 2 weeks. They will give regular blood, urine and stool samples during their stay and will be closely monitored. The men will return to the clinic about 1 week later for a final safety check.
Conditions
- Healthy Volunteer
Interventions
14C-labeled ASP3082Drug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK) of 14C-labeled ASP3082 (radioactivity in whole blood): area under the concentration-time curve from the time of dosing extrapolated to time infinity (AUCinf)Time frame: Up to 21 days
- PK of 14C-labeled ASP3082 (radioactivity in whole blood): area under the concentration-time curve from the time of dosing to the last measurable concentration (AUClast)Time frame: Up to 21 days
- PK of 14C-labeled ASP3082 (radioactivity in whole blood): maximum concentration (Cmax)Time frame: Up to 21 days
- PK of 14C-labeled ASP3082 (radioactivity in plasma): AUCinfTime frame: Up to 21 days
- PK of 14C-labeled ASP3082 (radioactivity in plasma): AUClastTime frame: Up to 21 days
- PK of 14C-labeled ASP3082 (radioactivity in plasma): CmaxTime frame: Up to 21 days
- PK of 14C-labeled ASP3082 (radioactivity ratio of whole blood/plasma concentrations): radioactivity ratio of area under the concentration time curve in blood as compared to plasma (AUCblood/AUCplasma)Time frame: Up to 21 days
- Excretion of 14C-labeled ASP3082 (radioactivity in urine): amount of administered dose excreted (Ae)Time frame: Up to 21 days
- Excretion of 14C-labeled ASP3082 (radioactivity in urine): percentage of administered dose excreted (Ae percentage)Time frame: Up to 21 days
- Excretion of 14C-labeled ASP3082 (radioactivity in urine): cumulative (over more than 1 sampling interval) amount of administered dose excreted (CumAe)Time frame: Up to 21 days
- Excretion of 14C-labeled ASP3082 (radioactivity in urine): renal clearance (CLr)Time frame: Up to 21 days
- Excretion of 14C-labeled ASP3082 (radioactivity in feces): AeTime frame: Up to 21 days
- Excretion of 14C-labeled ASP3082 (radioactivity in feces): Ae percentageTime frame: Up to 21 days
- Excretion of 14C-labeled ASP3082 (radioactivity in feces): CumAeTime frame: Up to 21 days
- Excretion of 14C-labeled ASP3082 (combined radioactivity in urine and feces): AeTime frame: Up to 21 days
- Excretion of 14C-labeled ASP3082 (combined radioactivity in urine and feces): Ae percentageTime frame: Up to 21 days
- Excretion of 14C-labeled ASP3082 (combined radioactivity in urine and feces): CumAeTime frame: Up to 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit Inc.
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.